DigestRedComo funciona
Red
/
Empresas
Ag
No verificado

Agomab Therapeutics NV

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

5 Comunicados de prensa

Ver todos los comunicados de prensa
10/04/2025
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
Fuente
Agomab Therapeutics NV
Editor
Business Wire
1.00
0
10/03/2025
Industria
Salud
Ciencia
Medicina - Varios
Farmacéutica
Biotecnología
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Fuente
Agomab Therapeutics NV
Editor
Business Wire
1.00
0
25/10/2024
Industria
Salud
Ciencia
Medicina - Varios
Farmacéutica
Biotecnología
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline
Fuente
Agomab Therapeutics NV
Editor
Business Wire
1.00
0
11/07/2024
Mercado laboral
Salud
Ciencia
Farmacéutica
Biotecnología
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Fuente
Agomab Therapeutics NV
Editor
Business Wire
1.00
0
09/07/2024
Mercado laboral
Salud
Ciencia
Farmacéutica
Biotecnología
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Fuente
Agomab Therapeutics NV
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0